Hepatic and glucagon-like peptide-1–mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors
J. Clin. Invest. Kyle W. Sloop, et al. 113:1571 doi:10.1172/JCI20911 [Go to this article.]

Figure 5
GCGR ASO treatment decreases glucagon binding to liver membranes. Glucagon binding to liver membranes was assessed by homologous competition in the presence of 0.1 nM ¹²⁵I-labeled glucagon in filter binding analysis as described in Methods. Results are expressed in fmol/mg membrane. Each value represents the mean ± SEM of duplicate conditions from the liver membranes of 11-week-old db/db mice (n = 3 per treatment group), which had been treated twice per week (every 3.5 days) by subcutaneous injection with control ASO 141923 (filled inverted triangles) or GCGR ASO 180475 (open circles). Receptor expression as percentage of control is shown in the inset. The white bar represents the average B_max ± SEM for GCGR ASO–treated samples versus control ASO (gray bar) (P < 0.05).